Document is current

Article History

Received: 22 September 2018

Accepted: 22 August 2019

First Online: 29 August 2019

Ethics approval and consent to participate

: This data review and analysis was approved by the Emory University Institutional Review Board (IRB), and waiver of consent was granted due to the retrospective nature of this study. All patients provided written informed consent for the phase 1 clinical trial to which they were enrolled, also reviewed and approved by the Emory University IRB.

: Not applicable.

: BCC has a consulting/advisory role with Astellas Medivation, Pfizer, and Blue Earth Diagnostics and receives travel accommodations from Bristol-Myers Squibb. WLS receives research funding from ArQule and Lilly. RP has a consulting/advisory role with Natera and AstraZeneca and receives travel accommodations from Genentech/Roche, Takeda, Novartis, and Clovis Oncology. She also receives research funding from Bristol-Myers Squibb. CW receives honorarium from BioTheranostics and research funding from Amgen, Bristol-Myers Squibb, Vaccinex, and Boston Biomedical. RRK has a consulting/advisory role with Bristol-Myers Squibb, Novartis, and Array BioPharma. She also receives honorarium from Bristol-Myers Squibb and research funding from Merck. BFE has a consulting/advisory role with Merrimack, BTG, Bayer, Loxo, and RTI Health Solutions. He is a member of the speakers’ bureau of Lexicon and Bristol-Myers Squibb. He also receives honorarium from Lexicon, RTI Health Solutions, and Bayer and received research funding from Taiho Pharmaceutical, Bristol-Myers Squibb, Boston Biomedical, Cleave Biosciences, Genentech, AVEO, Pfizer, Novartis, Hoosier Cancer Research Network, Five Prime Therapeutics, PPD Inc., Merck, and ICON Clinical Research. SSR has a consulting/advisory role with Amgen, Boehringer Ingelheim, Celgene, Genetech/Roche, Lilly/ImClone, Bristol-Myers Squibb, AstraZeneca, Abbvie, Merck, and Takeda and receives travel accommodations from EMD Serono, Pfizer, and AstraZeneca. TKO has a consulting/advisory role with Novartis, Bristol-Myers Squibb, and MedImmune. MAB has a consulting/advisory role with Exelixis, Sanofi and Nektar and receives research funding from Bayer, Bristol-Myers Squibb, Genentech/Roche, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Peleton, and Pfizer.